Lonza Confirms Full-Year Outlook After Robust Q3 Growth

MT Newswires

Oct 23, 2025

Lonza (SGX:O6Z) confirmed its full-year guidance after a strong third-quarter showing for its contract development and manufacturing organization (CDMO) business, according to a Thursday filing with the Singapore Exchange.

The Swiss contract drug manufacturer said its CDMO business remains on track for constant exchange rate (CER) sales growth of 20% to 21% and a core EBITDA margin of 30% to 31%.

Excluding the Vacaville contribution, organic CDMO sales growth is expected in the low teens.

The company also confirmed its outlook for the capsules & health ingredients segment, forecasting low- to mid-single-digit CER sales growth and a mid-twenties margin for the year.

Lonza said it expects no material financial impact from U.S. trade policy changes and continues to monitor biotech funding trends, noting stable utilization in its early-stage business.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2577024378"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2577024378\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2577024378?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-23 15:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2577024378","market":"sg","top_or_hot":-1,"title":"Lonza Confirms Full-Year Outlook After Robust Q3 Growth","media":"MT Newswires","content":"<html><body><p> Lonza (SGX:O6Z) confirmed its full-year guidance after a strong third-quarter showing for its contract development and manufacturing organization (CDMO) business, according to a Thursday filing with the Singapore Exchange.</p><p>The Swiss contract drug manufacturer said its CDMO business remains on track for constant exchange rate (CER) sales growth of 20% to 21% and a core EBITDA margin of 30% to 31%.</p><p>Excluding the Vacaville contribution, organic CDMO sales growth is expected in the low teens.</p><p>The company also confirmed its outlook for the capsules &amp; health ingredients segment, forecasting low- to mid-single-digit CER sales growth and a mid-twenties margin for the year.</p><p>Lonza said it expects no material financial impact from U.S. trade policy changes and continues to monitor biotech funding trends, noting stable utilization in its early-stage business.</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lonza Confirms Full-Year Outlook After Robust Q3 Growth</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLonza Confirms Full-Year Outlook After Robust Q3 Growth\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1060499803\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires </p>\n<p class=\"h-time\">2025-10-23 15:27</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Lonza (SGX:O6Z) confirmed its full-year guidance after a strong third-quarter showing for its contract development and manufacturing organization (CDMO) business, according to a Thursday filing with the Singapore Exchange.</p><p>The Swiss contract drug manufacturer said its CDMO business remains on track for constant exchange rate (CER) sales growth of 20% to 21% and a core EBITDA margin of 30% to 31%.</p><p>Excluding the Vacaville contribution, organic CDMO sales growth is expected in the low teens.</p><p>The company also confirmed its outlook for the capsules &amp; health ingredients segment, forecasting low- to mid-single-digit CER sales growth and a mid-twenties margin for the year.</p><p>Lonza said it expects no material financial impact from U.S. trade policy changes and continues to monitor biotech funding trends, noting stable utilization in its early-stage business.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK6506","symbol_name":"制药与医学研究概念","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2577024378","we_media_id":"1060499803","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2577024378","pubTimestamp":1761204451,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"MT Newswires","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1060499803","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Lonza  confirmed its full-year guidance after a strong third-quarter showing for its contract development and manufacturing organization  business, according to a Thursday filing with the Singapore Exchange.The Swiss contract drug manufacturer said its CDMO business remains on track for constant exchange rate  sales growth of 20% to 21% and a core EBITDA margin of 30% to 31%.Excluding the Vacaville contribution, organic CDMO sales growth is expected in the low teens.The company also confirmed its outlook for the capsules & health ingredients segment, forecasting low- to mid-single-digit CER sales growth and a mid-twenties margin for the year.Lonza said it expects no material financial impact from U.S. trade policy changes and continues to monitor biotech funding trends, noting stable utilization in its early-stage business.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK6506":"制药与医学研究概念","O6Z.SI":"龙沙"},"translate_title":"龙沙在第三季度强劲增长后确认全年前景","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"O6Z.SI":0.9},"content_text":"Lonza (SGX:O6Z) confirmed its full-year guidance after a strong third-quarter showing for its contract development and manufacturing organization (CDMO) business, according to a Thursday filing with the Singapore Exchange.The Swiss contract drug manufacturer said its CDMO business remains on track for constant exchange rate (CER) sales growth of 20% to 21% and a core EBITDA margin of 30% to 31%.Excluding the Vacaville contribution, organic CDMO sales growth is expected in the low teens.The company also confirmed its outlook for the capsules & health ingredients segment, forecasting low- to mid-single-digit CER sales growth and a mid-twenties margin for the year.Lonza said it expects no material financial impact from U.S. trade policy changes and continues to monitor biotech funding trends, noting stable utilization in its early-stage business.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}